glp-1 receptor agonists in idiopathic intracranial hypertension Use of glucagon-like peptide-1 : a systematic review | The Journal of Headache and Pain GLP-1 Receptor Agonists in Idiopathic
Description
However, it acts in contrast with GLP-1 as much as glucagon release is concerned by enhancing its release
The drugs of interest included FDA-approved GLP-1RAs [26]: semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, and albiglutide
Preclinical models have suggested a potential biological pathway through which GLP-1RAs could increase PDAC risk
Therefore, the choice between Mounjaro vs Ozempic in type 2 diabetes should depend on medical advice as well as individual treatment goals
Regulators are responding to this expansion with increased oversight
